Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

About this update from Rigel Pharmaceuticals, Inc.

[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 3:00 p.m. PT (6:00 p.m. ET).","length":435,"tagName":"p"},{"type":"text","content":"To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.","length":247,"tagName":"p"},{"type":"text","content":"About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.","length":433,"tagName":"p"},{"type":"text","content":"Contact for Investors & Media:Investors: Rigel Pharmaceuticals, Inc. 650.624.1232 [email protected]","length":117,"tagName":"p"},{"type":"text","content":"Media:David Rosen Argot Partners [email protected]","length":88,"tagName":"p"},{"type":"image","alt":"Rigel Pharmaceuticals Logo (PRNewsfoto/Rigel Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"Rigel Pharmaceuticals Logo (PRNewsfoto/Rigel Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":360,"height":216,"url":"https://media.zenfs.com/en/prnewswire.com/6d5d4ea80b797a53937d37e2b5610bea"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r.iSRYgiUJa1Zyjd9KnCpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQyMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/6d5d4ea80b797a53937d37e2b5610bea","width":360,"height":216}},"href":"https://mma.prnewswire.com/media/681135/Rigel_R_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"image","alt":"Cision","dis...

More updates from Rigel Pharmaceuticals, Inc.